This comprehensive review explores advances in RP-HPLC methods for stability testing of anti-malarial combinations, indicating potential for improved treatments.
Fixed-dose combinations (FDCs) of anti-malarial drugs play a crucial role in global malaria control by improving therapeutic efficacy, enhancing patient compliance, and minimizing resistance development. As these products often contain chemically diverse actives such as artemisinin derivatives, Lumefantrine, Amodiaquine, Mefloquine, Piperaquine, and Sulfadoxine-Pyrimethamine robust stability-indicating analytical methods are essential to ensure safety, efficacy, and regulatory compliance. Reversed-phase high-performance liquid chromatography (RP-HPLC) remains the most widely adopted analytical platform for stability studies due to its high resolution, reproducibility, selectivity, and compatibility with a broad range of pharmaceutical matrices. This comprehensive review summarizes the recent advances in stability-indicating RP-HPLC method development for anti-malarial FDCs, focusing on chromatographic conditions, forced degradation studies, validation parameters, green analytical initiatives, and Quality by Design (QbD) strategies. Current trends emphasize eco-friendly solvents, miniaturized sample preparation, novel stationary phases, and regulatory alignment with ICH Q1A (R2) and Q2 (R2). Critical challenges and future prospects for analytical improvement in anti-malarial quality control are highlighted.
No takes yet. Share an insight, caveat, or question.
Sarvepalli Gnana Samanvitha1, Shweta Purohit Nayak1*, Shaik Naziya Fathima1, MD. Saniya1, Mallani Sirisha1, Arunabha Mallik2 (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: